For this reason, imaging with FDG-PET/CT should be delayed at least 8 weeks following therapy and is preferred to occur at a minimum of 12 weeks after completion of therapy to allow for treatment effects to subside [110]. Concurrent infection can similarity give false positive findings. The use of FDG-PET/CT to evaluate for local recurrence may not confer benefit over CECT and MRI [153] but may have benefit in follow-up imaging of high-grade salivary gland tumors because of the increased frequency of distant metastases [108,114]. FDG-PET/MRI Skull Base to Mid-Thigh FDG-PET/MRI is new imaging modality with a growing body of evidence demonstrating the feasibility of use for routine clinical imaging, including the initial staging of major salivary gland tumor, with FDG-PET/MRI performing similarly to FDG-PET/CT. A study comparing FDG-PET/MRI to MRI concluded that FDG-PET/MRI is superior to MRI alone in the detection of local disease recurrence and locoregional nodal metastases in patients with adenoid cystic carcinoma [152]. Also, hybrid FDG-PET/MRI was found to be superior to conventional MRI in its NPV [137]. A separate study suggests FDG-PET/MRI is superior to PET/CT in the setting of salivary gland Assessment of Head and Neck Cancer tumors because of its improved characterization of internal tumor features and because of the propensity of these malignancies to present with perineural tumor spread [154]. MRA Neck With IV Contrast There is no relevant literature to support the routine use of MRA of the head with IV contrast in the follow-up imaging or the evaluation of known or suspected recurrence of treated cancer of a major salivary gland. MRA Neck Without and With IV Contrast There is no relevant literature to support the routine use of MRA of the head with and without IV contrast in the follow-up imaging or the evaluation of known or suspected recurrence of treated cancer of a major salivary gland.
Staging and Post Therapy Assessment of Head and Neck Cancer. For this reason, imaging with FDG-PET/CT should be delayed at least 8 weeks following therapy and is preferred to occur at a minimum of 12 weeks after completion of therapy to allow for treatment effects to subside [110]. Concurrent infection can similarity give false positive findings. The use of FDG-PET/CT to evaluate for local recurrence may not confer benefit over CECT and MRI [153] but may have benefit in follow-up imaging of high-grade salivary gland tumors because of the increased frequency of distant metastases [108,114]. FDG-PET/MRI Skull Base to Mid-Thigh FDG-PET/MRI is new imaging modality with a growing body of evidence demonstrating the feasibility of use for routine clinical imaging, including the initial staging of major salivary gland tumor, with FDG-PET/MRI performing similarly to FDG-PET/CT. A study comparing FDG-PET/MRI to MRI concluded that FDG-PET/MRI is superior to MRI alone in the detection of local disease recurrence and locoregional nodal metastases in patients with adenoid cystic carcinoma [152]. Also, hybrid FDG-PET/MRI was found to be superior to conventional MRI in its NPV [137]. A separate study suggests FDG-PET/MRI is superior to PET/CT in the setting of salivary gland Assessment of Head and Neck Cancer tumors because of its improved characterization of internal tumor features and because of the propensity of these malignancies to present with perineural tumor spread [154]. MRA Neck With IV Contrast There is no relevant literature to support the routine use of MRA of the head with IV contrast in the follow-up imaging or the evaluation of known or suspected recurrence of treated cancer of a major salivary gland. MRA Neck Without and With IV Contrast There is no relevant literature to support the routine use of MRA of the head with and without IV contrast in the follow-up imaging or the evaluation of known or suspected recurrence of treated cancer of a major salivary gland.